AR016264A1 - Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha - Google Patents

Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha

Info

Publication number
AR016264A1
AR016264A1 ARP990102133A ARP990102133A AR016264A1 AR 016264 A1 AR016264 A1 AR 016264A1 AR P990102133 A ARP990102133 A AR P990102133A AR P990102133 A ARP990102133 A AR P990102133A AR 016264 A1 AR016264 A1 AR 016264A1
Authority
AR
Argentina
Prior art keywords
cell
expression
gene
endogeno
ifna2
Prior art date
Application number
ARP990102133A
Other languages
English (en)
Spanish (es)
Original Assignee
Docampo Palacios Maite L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Docampo Palacios Maite L filed Critical Docampo Palacios Maite L
Publication of AR016264A1 publication Critical patent/AR016264A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP990102133A 1998-05-07 1999-05-06 Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha AR016264A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8464898P 1998-05-07 1998-05-07
US8655598P 1998-05-21 1998-05-21

Publications (1)

Publication Number Publication Date
AR016264A1 true AR016264A1 (es) 2001-06-20

Family

ID=26771248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102133A AR016264A1 (es) 1998-05-07 1999-05-06 Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha

Country Status (14)

Country Link
EP (1) EP1075531A1 (cs)
JP (1) JP2002513580A (cs)
KR (1) KR20010052278A (cs)
CN (1) CN1309710A (cs)
AR (1) AR016264A1 (cs)
AU (1) AU3788899A (cs)
CA (1) CA2328459A1 (cs)
CZ (1) CZ299418B6 (cs)
HU (1) HUP0102517A3 (cs)
IL (1) IL139433A0 (cs)
NO (1) NO20005585L (cs)
PL (1) PL344517A1 (cs)
TR (1) TR200003271T2 (cs)
WO (1) WO1999057292A1 (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
WO2012139195A1 (en) * 2011-04-13 2012-10-18 National Research Council Of Canada EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNα2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery

Also Published As

Publication number Publication date
HUP0102517A3 (en) 2004-06-28
WO1999057292A9 (en) 1999-12-16
NO20005585D0 (no) 2000-11-06
IL139433A0 (en) 2001-11-25
EP1075531A1 (en) 2001-02-14
CN1309710A (zh) 2001-08-22
NO20005585L (no) 2001-01-05
TR200003271T2 (tr) 2001-03-21
KR20010052278A (ko) 2001-06-25
CZ20003705A3 (cs) 2001-04-11
AU3788899A (en) 1999-11-23
JP2002513580A (ja) 2002-05-14
WO1999057292A1 (en) 1999-11-11
PL344517A1 (en) 2001-11-05
HUP0102517A2 (hu) 2001-11-28
CZ299418B6 (cs) 2008-07-16
CA2328459A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
AU2020259548B2 (en) Methods and compositions for editing RNAs
EP3443001B1 (en) REGULATED BIOCIRCUIT SYSTEMS
US5908779A (en) Targeted RNA degradation using nuclear antisense RNA
GB2617658A (en) Class II, type V CRISPR systems
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
CN113286880A (zh) 调控基因组的方法和组合物
CN116042611A (zh) 编辑rna的方法和组合物
AR005568A1 (es) Moleculas y construcciones de adn para aumentar la expresion de genes foraneos; celulas y plantas transformadas y metodo para producirlas
CN105316337A (zh) 嗜热链球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
CN105316324A (zh) 嗜热链球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
CN105331608A (zh) 脑膜炎双球菌CRISPR-Cas9系统识别的人CXCR4基因的靶序列和sgRNA及其应用
WO2002014495B1 (en) Enhanced homologous recombination mediated by lambda recombination proteins
RU2012130149A (ru) Векторная система на основе aslv
AR016263A1 (es) Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio
AR016262A1 (es) Una construccion de adn que altera la expresion de un gen pshbeta endogeno, una celula homologamente recombinante, un metodo para alterar la expresion dela fshbeta endogeno en la celula de un mamifero, uso de dicha celula para la manufactura de un medicamento, un metodo para producir fshbeta y una m
US20250243516A1 (en) Dual Cut Retron Editors for Genomic Insertions and Deletions
US20230383252A1 (en) Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy
US20230383253A1 (en) Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy
AR016264A1 (es) Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha
US20250215422A1 (en) RT-DNA Fidelity and Retron Genome Editing
EP4499849A1 (en) Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
JPS6486874A (en) Cloned dna containing transcription promoting factor s-ii, its fragment, preparation thereof, plasmid containing said cloned dna or fragment and method for diagnosing viral disease and cancer using said cloned dna or fragment
US20230193243A1 (en) Compositions comprising a cas12i2 polypeptide and uses thereof
WO2022140340A1 (en) Compositions comprising an rna guide targeting dmd and uses thereof
Kless et al. Photosystem II function and integrity in spite of drastic protein changes in a conserved region of the D2 protein

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal